Overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) occurs in approximately 20% of all breast cancers, which is associated with more aggressive tumours with a high risk of recurrence and poor prognosis [1]. This evidence concerns the gene ERBB2 and breast carcinoma.